Cosmos Health

Cosmos Health Current Assets

The Current Assets of Cosmos Health (COSM) as of Oct 21, 2026 is 15.83 M USD. In the previous year, Current Assets was 25.46 M USD — a change of -37.84% (lower).

Current Assets

15.83 MUSD

YoY

-37.84%

Last updated:

Current Assets of Cosmos Health is 2025 15.83 M USD. Current Assets of Cosmos Health was 2024 25.46 M USD. It decreases by -37.84% lower compared to the previous year.

The Cosmos Health Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
13.93 M USD
Jan 1, 2019
21.18 M USD
Jan 1, 2020
40.77 M USD
Jan 1, 2021
34.63 M USD
Jan 1, 2022
59.68 M USD
Jan 1, 2023
32.75 M USD
Jan 1, 2024
25.46 M USD
Jan 1, 2025
15.83 M USD
The Cosmos Health Current Assets history
YEARCurrent AssetsYoY
15.83 MUSD-37.84%
25.46 MUSD-22.27%
32.75 MUSD-45.12%
59.68 MUSD+72.36%
34.63 MUSD-15.08%
40.77 MUSD+92.50%
21.18 MUSD+52.01%
13.93 MUSD+46.46%
9.51 MUSD+261.34%
2.63 MUSD+378.15%
550,632.00USD-92.37%
7.21 MUSD+733.94%
864,924.00USD—
0.00USD-100.00%
15,238.00USD+3,142.13%
470.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmos Health Stock analysis

What does Cosmos Health do? Cosmos Health Inc generates revenue through the importation, exportation, distribution, and sale of branded pharmaceuticals, over-the-counter medicines, and generic pharmaceuticals. The company leverages its subsidiary Amplerissimo Ltd., which provides data mining, statistical data analysis, research, and consulting services including credit risk analysis, marketing management, and business management software consulting. SkyPharm S.A., a subsidiary of Amplerissimo, trades branded and generic pharmaceutical products across the European Union member states, contributing to the company's revenue streams. Clients include sectors requiring pharmaceutical distribution, consulting services, and EU market access for medicines. Amplerissimo's services target businesses needing data-driven insights, credit management, and strategic consulting, while SkyPharm serves the European pharmaceutical market with a focus on branded and generic products. The company's revenue model combines direct product sales with specialized consulting services, catering to both domestic and international clients in the pharmaceutical industry. This dual approach allows Cosmos Health Inc to address diverse market needs through its subsidiaries and core operations. The firm's primary buyers are pharmaceutical distributors, healthcare providers, and businesses seeking consulting services for market expansion, data analysis, and credit management. Amplerissimo's consulting services support clients in sectors requiring strategic planning, while SkyPharm's trading activities serve EU-based pharmaceutical companies and distributors. Cosmos Health Inc's revenue is derived from product sales and service contracts, with no mention of additional revenue streams beyond the described operations. Cosmos Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmos Health stock

Current Assets of Cosmos Health is 15.83 M USD in 2025.

Current Assets of Cosmos Health changed from 25.46 M USD to 15.83 M USD, representing a -37.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Cosmos Health since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Cosmos Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmos Health

All Key Metrics — Cosmos Health